- Home
- CHH vs VKTX Comparison
CHH vs VKTX Comparison
Compare CHH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHH | VKTX |
|---|---|---|
| Founded | 1939 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CHH | VKTX |
|---|---|---|
| Price | $108.54 | $33.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $114.30 | $95.86 |
| AVG Volume (30 Days) | 460.5K | ★ 1.8M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 27.42 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $1,596,793,000.00 | N/A |
| Revenue This Year | $66.74 | N/A |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $59.71 | ★ N/A |
| Revenue Growth | ★ 0.75 | N/A |
| 52 Week Low | $84.04 | $22.96 |
| 52 Week High | $123.82 | $43.15 |
Technical Indicators
Market Signals| Indicator | CHH | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 48.67 |
| Support Level | $103.66 | $33.89 |
| Resistance Level | $110.35 | $35.67 |
| Average True Range (ATR) | 2.76 | 1.32 |
| MACD | 0.45 | 0.11 |
| Stochastic Oscillator | 69.37 | 41.79 |
Price Performance
Historical ComparisonAbout CHH Choice Hotels International Inc.
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.